GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mirodenafil   Click here for help

GtoPdb Ligand ID: 11738

Synonyms: AR-1001 | AR1001 | Mvix® | SK-3530 | SK3530
Approved drug
mirodenafil is an approved drug (Korea (2007))
Compound class: Synthetic organic
Comment: Mirodenafil (SK-3530; AR1001) is a selective, oral phosphodiesterase type 5 (PDE5). PDE5 inhibitors are the most widely used drugs to treat erectile dysfunction [4]. Formulated as the hydrochloride salt for clinical use.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

mirodenafil is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 129.14
Molecular weight 531.25
XLogP 2.71
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCCOc1ccc(cc1c1[nH]c(=O)c2c(n1)c(CCC)cn2CC)S(=O)(=O)N1CCN(CC1)CCO
Isomeric SMILES CCCc1cn(c2c1nc([nH]c2=O)c1c(ccc(c1)S(=O)(=O)N1CCN(CC1)CCO)OCCC)CC
InChI InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)
InChI Key MIJFNYMSCFYZNY-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B et al.. (2025)
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.
J Prev Alzheimers Dis, 12 (9): 100337. [PMID:40912996]
2. Lee SW, Son H, Lee SW, Cho KS, Moon DG, Yang DY, Chung WS, Suh JK, Park HJ, Min K et al.. (2022)
Efficacy and Safety of Mirodenafil Oro-Dispersible Film in Korean Patients with Erectile Dysfunction: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Phase IV Study.
World J Mens Health, 40 (2): 280-289. [PMID:33987996]
3. Naef R, Tenor H. (2021)
Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof.
Patent number: US11155558B2. Assignee: Topadur Pharma AG. Priority date: 22/05/2018. Publication date: 26/10/2021.
4. Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC. (2014)
Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.
World J Mens Health, 32 (1): 18-27. [PMID:24872948]
5. Shin HI, Lee D, Kim DK. (2006)
Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-n-propoxyphenyl}-7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2-14C]pyrimidin-4-one·2 HCl (14C-SK3530·2 HCl).
J Label Compd Radiopharm, 49: 1141-1149. DOI: 10.1002/jlcr.1116